Aquavit Pharmaceuticals has launched its Aquagold fine touch, an innovative device incorporating microneedles smaller than a human hair to deliver a substantial volume of medication directly into the dermis.
Aquagold fine touch delivers medication in a pain-free and non-traumatic fashion to sensitive areas on the face, hands and elsewhere on the body. The first-of-its-kind has received the US Food and Drug Administration and CE Mark approvals.
Aquavit Pharmaceuticals chief medical officer Dr David Goldberg said: "Aquagold fine touch reduces the risk of bruising and swelling, allowing treatment around the mouth, eyes and other areas that are hard to treat with traditional methods of delivery."
According to the company, the direct dermal application technology addresses the unmet needs of the $11bn medical aesthetics market and the $30bn vitamin and mineral market.
Aquavit Pharmaceuticals CEO Sobin Chang noted launching Aquagold fine touch is a major milestone for the company.
"We have been extremely focused on our technological innovations in personalized medicine and we have been overwhelmed with the positive responses we have received at this meeting today," Chang added.
Aquavit Pharmaceuticals has launched the Aquagold fine touch at the annual meeting for the American Academy of Dermatology. The company, at this meeting, is also accepting applications for clinical investigators.
Image: Aquavit Pharmaceuticals announces official launch of Aquagoldfine touch. Photo: Courtesy of PRnewswire/Aquavit Pharmaceuticals, Inc.